These stories made today's top 10 list of articles and videos on TheStreet.
The purchase of Allos Therapeutics cannot make up for the loss of Spectrum's bladder cancer drug.
Shares of Allos Therapeutics (Nasdaq:ALTH) were gapping down Friday morning with an open price 15.1% lower than Thursday's closing price. The stock closed at $1.66 yesterday and opened today's trading at $1.41.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Shareholders rejected the merger between Amag and Allos, sending a clear message that big changes are needed fast.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.